| 000 | 01505nam a2200265 4500 | ||
|---|---|---|---|
| 001 | ESSALUD | ||
| 005 | 20260902150847.0 | ||
| 007 | ta | ||
| 008 | t pe ||||| |||| 00| 0 spa d | ||
| 040 | _aBMG | ||
| 041 | _aeng | ||
| 100 |
_aSpyropoulos, Alex C. _eAutor _954428 |
||
| 245 | _aAdvanced Therapy for Intermediate-Risk Pulmonary Embolism | ||
| 300 | _apáginas: 2052-2054 | ||
| 520 | _aPulmonary embolism is the third leading cardiovascular cause of complications and death after myocardial infarction and stroke, with a rising incidence globally. The approach to management of acute pulmonary embolism as a condition to be treated nonsurgically with systemic heparin anticoagulation was established more than 60 years ago. Patients with high-risk pulmonary embolism and cardiogenic shock appear to benefit from early thrombus removal, with rapid reductions in pulmonary obstruction and pulmonary vascular resistance from baseline and a lower risk of death than with anticoagulation alone, but at the cost of a nearly 10% risk of major bleeding. | ||
| 650 |
_aANTICOAGULACIÓN _953834 |
||
| 650 |
_aTROMBOEMBOLISMO _932218 |
||
| 650 |
_aCARDIOLOGÍA _911301 |
||
| 650 |
_aNEUMOLOGÍA _925628 |
||
| 650 |
_aMEDICINA CLÍNICA HOSPITALARIA _953754 |
||
| 650 |
_aRADIOLOGÍA GENERAL _954381 |
||
| 700 |
_aVedantham, Suresh _953896 |
||
| 773 | 0 |
_022717 _922665 _dMassachusetts NEJM Group _oNEJM013 _tThe New England Journal of Medicine _wESSALUD _x0028-4793 |
|
| 942 |
_cARTICULOS _e2026-08-28 _zsqb |
||
| 999 |
_c22891 _d22891 |
||